Autoimmune Chronic Hepatitis – Talk Bio

Actionable Insights Powered by AI

Kezar Initiates Strategic Review After FDA Setback; Taysha Regains Full Rights to Rett Syndrome Program as Astellas Agreement Ends

6 days ago talkbio0Tagged Astellas, Autoimmune Chronic Hepatitis, Clinical Trials, Kezar Life Sciences, Rett Syndrome, setback, strategic alternatives, Taysha Gene Therapies, TSHA-102, United States Food and Drug Administration, Zetomipzomib

Kezar Life Sciences; FDA setback; strategic alternatives; zetomipzomib; autoimmune hepatitis; Taysha Gene Therapies; Astellas; Rett syndrome; TSHA-102; clinical trials

FDA Issues Second Clinical Hold on Kezar’s Zetomipzomib Program Within Two Months

12 months ago talkbio0Tagged Autoimmune Chronic Hepatitis, Clinical Trials, Kezar Life Sciences, Lupus Nephritis, Study on Hold, United States Food and Drug Administration, Zetomipzomib

Kezar Life Sciences, Zetomipzomib, FDA Clinical Hold, Lupus Nephritis, Autoimmune Hepatitis, Clinical Trials